Currently in clinical practice are becoming more common so-called respiratory fluoroquinolones, which on one hand, preserve the activity of the early fluoroquinolones (eg ciprofloxacin) against gram-negative organisms, but on the other – are more active against pneumococci and atypical bacteria.
Levofloxacin, the active component of Levaquin, is the most studied substance among respiratory fluoroquinolones. It has been prescribed to more than 300 million patients worldwide. A number of clinical studies has confirmed Levaquin’s high efficacy and safety both in the traditional indications for this group of antibiotics, such as acute sinusitis, exacerbation of chronic bronchitis, community-acquired pneumonia, urinary tract infections, and in some other diseases: nosocomial pneumonia, chronic bacterial prostatitis. Currently, researchers continue to study the effectiveness of Levauin in pelvic infections, tuberculosis, as well as peptic ulcer (for eradication of Helicobacter pylori) and other diseases.
Levaquin indications:
traditional and new*
Respiratory tract infections:
• Acute sinusitis
• Bacterial exacerbation of chronic bronchitis
• Community-acquired pneumonia, including a short 5-day treatment course*. Levaquin is the first fluoroquinolone which can be used short-term in this disease, which improves the compliance of patients, reduces the quantity of intaken medicine, and possibly reduces the risk of selection of antibiotic-resistant strains.
• Community-acquired pneumonia caused by multiresistant strains of Streptococcus pneumoniae*. In a short-term administration of Levaquin in high doses (750 mg for 5 days), its clinical efficacy was 92,3-100%
• Legionella pneumonia*
• Nosocomial pneumonia*
Infections of skin and soft tissue
Urinary tract infections:
• Uncomplicated (including acute pyelonephritis)
• Complicated
• Chronic prostatitis*. Levaquin is the only fluoroquinolone, which can be used for chronic bacterial prostatitis once per day.
Spectrum of activity
Levaquin has a broad spectrum of activity that includes Gram-positive (Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes) and Gram-negative (Enterobacteriaceae, Haemophilus influenzae, Moraxellacatarrhalis, Pseudomonas aeruginosa) microorganisms. It should be noted the Levaquin’s high activity against pneumococci resistant to penicillin and other antibiotics. This medicine is more active than many other fluoroquinolones (ciprofloxacin, etc.) against atypical pathogens (Chlamydia spp., Mycoplasma spp.). For activity against Mycobacterium tuberculosis it comes before ciprofloxacin and ofloxacin.
Conclusion
Levaquin is highly effective and safe fluoroquinolone with a broad spectrum of activity, optimal pharmacokinetics, a convenient dosing regimen (once per day), availability of different forms of the medicine for intravenous and oral administration, which allows its wide use in the treatment of infections of different localization. In the future, it will be probably possible to use Levaquin for treatment of pulmonary tuberculosis.
More information about Levaquin you can get HERE
Genial brief and this post helped me alot in my college assignement. Thank you on your information.